Moreover, many reports suggest that the suppression of survivin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based cancer therapy that requires the incorporation of other anti-cancer agents because of its limited anti-cancer efficacy due to TRAIL-resistance [13,14,15,16,17]. The gene discussed is BIRC5; the disease is cancer.